Get the Stockscreener App
10.30
3.52%
0.35
Immunome Inc stock is traded at $10.30, with a volume of 1.04M.
It is up +3.52% in the last 24 hours and down -6.96% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$9.95
Open:
$10.16
24h Volume:
1.04M
Relative Volume:
1.19
Market Cap:
$896.56M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-3.1102
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
+0.19%
1M Performance:
-6.96%
6M Performance:
+8.19%
1Y Performance:
-29.36%
1-Day Range:
$10.04
$10.72
1-Week Range:
$9.3713
$10.72
52-Week Range:
$5.1501
$16.73
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.30 | 892.21M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Can Immunome Inc. rally from current levelsJuly 2025 Analyst Calls & Verified Momentum Stock Ideas - Newser
Does Immunome Inc. qualify in momentum factor screeningIndex Update & Safe Entry Zone Tips - Newser
Why Immunome Inc. stock attracts strong analyst attentionJuly 2025 Breakouts & Consistent Profit Focused Trading Strategies - Newser
Is a relief rally coming for Immunome Inc. holdersMarket Weekly Review & Accurate Technical Buy Alerts - Newser
Using Bollinger Bands to evaluate Immunome Inc.Buy Signal & Stock Portfolio Risk Management - Newser
Is It Too Late to Sell Immunome Inc.Weekly Stock Analysis & Weekly Hot Stock Watchlists - kangso.co.kr
Will breakout in Immunome Inc. lead to full recoveryEarnings Risk Summary & Real-Time Volume Analysis Alerts - Newser
Using Ichimoku Cloud for Immunome Inc. technicals2025 Winners & Losers & High Accuracy Trade Alerts - Newser
Will Immunome Inc. stock recover after recent dropEarnings Growth Report & Risk Controlled Daily Plans - Newser
Will Immunome Inc. continue its uptrendTrade Volume Report & Capital Efficiency Focused Strategies - Newser
How to forecast Immunome Inc. trends using time seriesJuly 2025 News Drivers & Short-Term High Return Strategies - Newser
Can Immunome Inc. maintain its current growth rate2025 Support & Resistance & Verified Entry Point Detection - sisa-n.com
Detecting support and resistance levels for Immunome Inc.Forecast Cut & Stock Market Timing Techniques - Newser
Immunome Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 Breakouts & High Win Rate Trade Tips - metal.it
Will Immunome Inc. Stock Benefit from AI and Green Energy TrendsCEO Change & Precise Entry and Exit Recommendations - Newser
What momentum shifts mean for Immunome Inc.Quarterly Earnings Report & Reliable Price Breakout Signals - Newser
Should you hold or exit Immunome Inc. nowJuly 2025 Spike Watch & Daily Chart Pattern Signal Reports - Newser
What’s next for Immunome Inc. stock priceJuly 2025 Patterns & Stock Market Timing Techniques - Newser
When is the best time to exit Immunome Inc.July 2025 Catalysts & Growth Focused Entry Point Reports - Newser
Will Immunome Inc. bounce back from current supportTrade Analysis Report & Verified Swing Trading Watchlists - Newser
Will earnings trigger a reversal in Immunome Inc.July 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
Chart based analysis of Immunome Inc. trendsJuly 2025 Price Swings & Short-Term Swing Trade Alerts - Newser
Multi asset correlation models including Immunome Inc.2025 Big Picture & Scalable Portfolio Growth Ideas - Newser
Will Immunome Inc. stock benefit from AI tech trendsWeekly Gains Report & Verified Momentum Stock Alerts - Newser
Fibonacci Retracement Aligns with Support in Immunome Inc.July 2025 EndofMonth & Community Verified Trade Signals - thegnnews.com
What makes Immunome Inc. stock attractive to long term investorsQuarterly Growth Report & AI Forecast for Swing Trade Picks - Newser
Trapped Investors in Immunome Inc. Await Breakout SignalWeekly Profit Recap & Daily Entry Point Trade Alerts - 선데이타임즈
Sectors Driving Future Growth for Immunome Inc. StockJuly 2025 Fed Impact & Advanced Technical Analysis Signals - Newser
Trendlines Converge — Decision Point for Immunome Inc.July 2025 Breakouts & High Accuracy Buy Signal Tips - 선데이타임즈
Short interest data insights for Immunome Inc.Weekly Risk Summary & Daily Profit Focused Screening - Newser
Immunome's Undervalued Gamma Secretase Inhibitor Pipeline in Light of SpringWorks' Merck Acquisition - AInvest
Immunome's SpringWorks Buyout Highlights Upside Potential - AInvest
Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha
What makes Immunome Inc. stock price move sharplyReal-Time AI Generated Market Forecast - Newser
Immunome Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Quant Tools Rank Immunome Inc. as High Risk High RewardChart Based Entries - beatles.ru
Wedbush Comments on Immunome’s Q3 Earnings (NASDAQ:IMNM) - Defense World
Research Analysts Offer Predictions for Immunome Q3 Earnings - Defense World
What recovery options are there for Immunome Inc.5-Year Price Trend Summary and Analysis - Newser
How Immunome Inc. stock performs during market volatilityLong-Term Allocation Strategy Summary Breakdown - Newser
Is Immunome Inc. benefiting from innovation trendsSmart Portfolio Allocation - newsyoung.net
A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $21 to $38 - 富途牛牛
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):